Personalized vaccine trial offers new hope for advanced kidney cancer patients
NCT ID NCT06708936
Summary
This is a very early study to check the safety and initial effects of a new personalized vaccine called KSD-201 for people with advanced kidney cancer that has stopped responding to standard treatments. Doctors will make the vaccine from the patient's own immune cells and give it as a series of injections. The main goal is to see if the treatment is safe and tolerable, while also looking for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA (CCRCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.